WATANABE AKIHIKO
No ORCID on file
· 90 papers in corpus
· active 2006-2007
Frequent coauthors
- KAWASAKI HIROKAZU 90
- OHSHIMA ETSUO 90
- KIMOTO NAOYA 75
- WATANABE AKIKO 15
2007
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
2007
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
2007
It is intended to provide a remedy for endometriosis which contains an interleukin-5 antagonist as the active ingredient.
2007
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
2007
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
2007
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
2007
It is intended to provide a remedy for endometriosis which contains an interleukin-5 antagonist as the active ingredient.
2007
It is intended to provide a remedy for endometriosis which contains an interleukin-5 antagonist as the active ingredient.
2007
It is intended to provide a remedy for endometriosis which contains an interleukin-5 antagonist as the active ingredient.
2007
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
2007
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
2007
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
2007
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
2007
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
2007
It is intended to provide a remedy for endometriosis which contains an interleukin-5 antagonist as the active ingredient.
2007
It is intended to provide a remedy for endometriosis which contains an interleukin-5 antagonist as the active ingredient.
2007
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
2007
It is intended to provide a remedy for endometriosis which contains an interleukin-5 antagonist as the active ingredient.
2007
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
2007
It is intended to provide a remedy for endometriosis which contains an interleukin-5 antagonist as the active ingredient.
2007
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
2007
It is intended to provide a remedy for endometriosis which contains an interleukin-5 antagonist as the active ingredient.
2007
It is intended to provide a remedy for endometriosis which contains an interleukin-5 antagonist as the active ingredient.
2007
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
2007
It is intended to provide a remedy for endometriosis which contains an interleukin-5 antagonist as the active ingredient.